 Tamorah R. Lewis, MD, PhD
| Title | Assistant Professor of Pediatrics |
|---|
| Institution | University of Missouri-Kansas City |
|---|
| Department | Pediatrics |
|---|
|
|---|
|
 Biography | Johns Hopkins Univ. SOM, Baltimore, MD | | 2007 | M.D. | | Johns Hopkins Univ. SOM, Baltimore, MD | | 2010 | Pediatric Residency | | Johns Hopkins Hospital, Baltimore, MD | | 2014 | Dual fellowship - Neonatology/Clinical Pharmacology | | Bloomberg School of Public Health, Baltimore, MD | | 2015 | PhD, Clinical Investigation |
Overview Research Dr. Lewis is a neonatologist and translational researcher in neonatal and perinatal Pharmacology. As an Assistant Professor in the Department of Pediatrics at The University of Missouri, Kansas City School of Medicine, she is a physician scientist, spending 25% of her time as an attending in our Level IV NICU and 75% of her time designing, implementing and managing clinical research programs in neonatal pharmacology at Children’s Mercy Hospital. The overarching goal of her research program is to bring precision therapeutics to the NICU population using modern pharmacology tools. The research program focuses on pharmacokinetics, pharmacodynamics and pharmacogenetics of both old and new drugs used to treat neonatal disease, with an emphasis on optimizing and individualizing drug therapy in neonates.
Dr. Lewis has established the Maternal Neonatal Pharmacogenetic Repository at Children’s Mercy Hospital and has multiple prospective pharmacogenetic cohort studies enrolling and depositing diverse samples to this repository. In addition, she is the recipient of a K23 from NICHD and the Robert Wood Johns Harold Amos Career Development award, both supporting ongoing neonatal pharmacology research.
Please feel free to contact her if interested in developmental pharmacology research.
1K23HD09136201A1 (Tamorah Lewis)Sep 1, 2018 - Aug 30, 2022 NICHD
Ontogeny and Genetics of NSAID Dose-Exposure Relationship in Preterm Infants
Role Description: Develop a dose-individualization tool based on combination of in vivo PK and genetic samples and in vitro hepatic microsomal studies. In addition, understand the pharmacometabolome of NSAID response for PDA closure in preterm infants. |
| Harold Amos Faculty Development Award #76230 (Tamorah Lewis)Jan 1, 2019 - Dec 31, 2022 Robert Wood Johnson Foundation
The effects of age and genetics on exposure to nonsteroidal anti-inflammatory drugs in premature infants |
Bibliography
-
Lewis T, Tolbert J, Jones BL. Increasing Resident Racial and Ethnic Diversity through Targeted Recruitment Efforts. J Pediatr. 2020 Jan; 216:4-6. PMID: 31843119.
-
Cammack B, Oschman A, Lewis T. Improving Recognition and Reporting of Adverse Drug Reactions in the NICU: A Quality Improvement Project. Pediatr Qual Saf. 2019 Sep-Oct; 4(5):e203. PMID: 31745506.
-
Donato J, Rao K, Lewis T. Pharmacology of Common Analgesic and Sedative Drugs Used in the Neonatal Intensive Care Unit. Clin Perinatol. 2019 12; 46(4):673-692. PMID: 31653302.
-
Lewis T, Chalise P, Gauldin C, Truog W. Pharmacometabolomics of Respiratory Phenotypic Response to Dexamethasone in Preterm Infants at Risk for Bronchopulmonary Dysplasia. Clin Transl Sci. 2019 Nov; 12(6):591-599. PMID: 31188532.
-
Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D. Correction: Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatr Res. 2019 Apr; 85(5):731. PMID: 30733615.
-
Lewis T. ECI biocommentary. Pediatr Res. 2019 04; 85(5):586. PMID: 30670773.
-
Cuna A, Lewis T, Dai H, Nyp M, Truog WE. Timing of postnatal corticosteroid treatment for bronchopulmonary dysplasia and its effect on outcomes. Pediatr Pulmonol. 2019 02; 54(2):165-170. PMID: 30537393.
-
Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D. Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatr Res. 2019 04; 85(5):625-633. PMID: 30467342.
-
Lewis T, Leeder JS. Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier? Pharmacogenomics. 2018 11; 19(16):1231-1233. PMID: 30334480.
-
Lewis T, Van Haandel L, Scott A, Leeder JS. Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing. Pediatr Res. 2018 09; 84(3):325-327. PMID: 29967531.
-
Lewis T, Kuye S, Sherman A. Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit. BMC Pediatr. 2018 06 20; 18(1):197. PMID: 29925342.
-
Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J. Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment. Semin Fetal Neonatal Med. 2018 08; 23(4):232-238. PMID: 29510900.
-
Lewis T. Precision therapeutics in the NICU: why are we missing the mark? J Perinatol. 2018 05; 38(5):444-446. PMID: 29379159.
-
Lewis T, Dinh J, Leeder JS. Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clin Pharmacol Ther. 2015 Sep; 98(3):309-20. PMID: 26058918.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2015 | 1 | | 2018 | 7 | | 2019 | 5 | | 2020 | 1 |
To return to the timeline, click here.
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|